Det er fond som selger ut en del.
Det et generelt børskrakk som finner sted om dagen også, selv om det ikke er så synlig på norsk indeks. Store aktører tar ned eksponering generelt, det treffer lavlikvide luringer som PHO (som tross alt har en ganske internasjonal eiersammensetning) også.
Jeg tenker tilbakekjøp så langt det er mulig på rundt 50-60 kan/bør være i alles interesse gitt utsiktene.
1 Like
Bladder Cancer presentations at AUA2025: Blue Light Cystoscopy improves risk stratification and informed decision making
8 Likes
Vil disse få en prising basert på tidligere kurs, altså at aksjekursen må stige for å være "in the money"eller er det basert på hva de priser aksjene til ved emisjon - altså 50øre?
@tooeasy891 du har jo peiling…
De blir vel satt ved bruk av black scholes metoden, og strike 10% over kursen da de blir gitt tror jeg. (Hvertfall fra års rapporten). Er jo uansett ganske få aksjer akkurat de der da😅
2 Likes
Dette innlegget ble rapportert og er midlertidig skjult.
Asieris will present Cevira trial data and showcase Hexvix at the IPA congress
PUBLISHED: 6 JUNE 2025MEDICAL CONGRESSES & EVENTSPARTNERSHIP NEWS & EXPANSION
Photocure partner Asieris provides an update on three Cevira (APL-1702) presentations, scheduled at the upcoming 19th International Photodynamic Association (IPA) Congress that will convene in Shanghai from June 10-16, 2025.
IPA 2025 will gather leading scholars, clinical experts, and industry leaders to explore cutting-edge advancements and the vast potential of PDT.During this meeting leading investigators will present APRICITY study efficacy and safety data and discuss latest clinical applications of PDT for cervical intraepithelial lesions. Asieris will also exhibit Hexvix (APL-1706) at this international conference, as it is currently approved in China.
Read Asieris’ full media release here: Asieris to Present World's Innovative Photodynamic Products at 19th IPA Congress - Asieris Pharmaceuticals
2 Likes
Feil tråd
2 Likes
Men det er jo ikke milepælsbetalingen som er gulroten her. Det er jo det som kommer etter ang. royalties på både hexvix og cysview… er jo der selve oppsiden ligger på sikt i forhold til Kina.
3 Likes
1 Like
Photocure ASA: Invitation to presentation of second quarter and first half year 2025 financial results
1 Like
12 Likes
10 Likes
«APL-1702, a breakthrough therapy for precancerous cervical lesions, is in the final stages before its China launch. Hexvix®, China’s first approved blue-light imaging agent for bladder cancer, marks a new era for photodynamic blue-light cystoscopy.»
« Breakthrough Innovation Poised for Imminent Market Impact
In women’s health, APL-1702, a first-in-class treatment set to debut in China, is on track to become the world’s first non-invasive therapy for high-grade squamous intraepithelial lesion (HSIL) of the cervix, supported by robust clinical evidence and validated in an international Phase III trial. Following the acceptance of its marketing application by China’s National Medical Products Administration (NMPA) in May 2024, the company has made APL-1702 a strategic priority. The regulatory review is progressing smoothly, with the NMPA having initiated a second round of technical evaluation.
APL-1702’s innovation, clinical promise, and societal value have earned strong endorsement from gynecology and pharmaceutical experts. With cervical lesions increasingly affecting younger women in China and current treatments relying on cervical excision, managing precancerous lesions during the critical fertility-preservation window has become a major challenge. Experts believe APL-1702 could address this unmet clinical need, transform the treatment landscape, and support the development of a fertility-friendly society.
To fast-track the commercialization of APL-1702, the company has undertaken multiple pre-launch initiatives. Phase III trial results have been presented at leading academic conferences, and more than 10 expert advisory meetings have been held to support updates to clinical guidelines and consensus. At the China International Import Expo, the product was showcased globally, and the company signed medium- to long-term strategic partnerships with the China Women’s Development Foundation and the Cancer Foundation of China. All of these projects were launched in the first half of 2025. To improve access and affordability, disease-burden and policy research have been conducted. The company is also accelerating the build-out of its commercial team, implementing an omni-channel strategy focused on public hospitals, and optimizing the supply chain to ensure patients can benefit immediately upon approval.
In urologic oncology, Hexvix®, China’s first approved imaging agent for bladder cancer, has ushered in a new era of blue-light cystoscopy. The company is actively supporting its partner R.WOLF in advancing the regulatory review of the SYSTEM BLUE blue-light cystoscopy system in China, with approval targeted by the end of 2025. Once approved, the system, combined with Hexvix®, is expected to improve outcomes for patients nationwide.
To expand market opportunities and strengthen strategic control, the company plans to introduce its single-use blue-light flexible cystoscope to China and accelerate regulatory approval. The aim is to allow patients to fully benefit from blue-light cystoscopy by avoiding unnecessary surgical trauma, preserving bladder function, enhancing quality of life, and reducing total five-year treatment costs through earlier diagnosis.
The company is refining its launch strategy for Hexvix®, initially targeting patients with strong willingness to pay out-of-pocket or coverage through commercial insurance, focusing on urology centers in top-tier and oncology hospitals in major cities. Over time, as clinical guidelines are updated and urology expert endorsements are established, coupled with the launch of single-use blue-light cystoscopes, the company plans to gradually expand penetration into urology centers across key hospitals nationwide, achieving broad access to blue-light cystoscopy.»
«In women’s health, breast cancer, and gynecologic oncology, the results of the international, multicenter Phase III trial of APL-1702 were selected for an oral presentation at the 2025 International Photodynamic Association (IPA) World Congress. The company has also reached agreement with the U.S. FDA on the design of another Phase III trial to support potential U.S. approval of APL-1702 and is seeking overseas partners to prepare for the U.S. IND submission»
«Dr. Kevin Pan, Founder, Chairman and CEO of Asieris Pharmaceuticals, commented, “In the first half of 2025, the company reached multiple milestones, steadily fulfilling our growth expectations. A remarkable achievement is the smooth progression of the regulatory review for APL-1702, our breakthrough therapy for precancerous cervical lesions, now entering the final stages ahead of its China launch and set to benefit patients soon.»
6 Likes